Clinical Trial Update: Idiopathic Focal Segmental Glomerulosclerosis (FSGS) and Treatment With ACTH [Phase 4]

View source ↗

Summary

This Phase 4 trial update reports results from using adrenocorticotropic hormone (ACTH) to treat idiopathic focal segmental glomerulosclerosis (FSGS).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Focal Segmental Glomerulosclerosis

Drugs mentioned

• Acthar Gel (repository corticotropin injection)

Snippet

Sponsor: Stanford University | Conditions: Kidney Diseases | Phase 4 | Status: COMPLETED | Results posted: 2014-09-01